FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer

Key Points

• FGTI-2734 improves efficacy against KRAS G12D pancreatic cancer, counteracting resistance mechanisms.
• Notably, MRTX1133 efficacy increases by 45% with the addition of FGTI-2734, indicating potential for better outcomes.
• Analysis utilized preclinical models to assess the combined treatment effects on tumor growth inhibition and resistance.
• These findings may enable more effective therapeutic strategies against resistant pancreatic cancer types.